NEW YORK,May 23, 2024/PRNewswire/ --Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that theAmerican Society of Clinical Oncology (ASCO)has published an abstract in its 2024...
2024 ASCO 2024年5月31日-6月4日,2024年美国临床肿瘤学会(ASCO)年会于美国芝加哥正式召开。中国医学论坛报学术联播持续关注大会前沿,推出“一分钟要闻”板块,为您网罗大会新鲜资讯,浓缩学术前沿精华! 研究概要 标题:2024ASCO年会重磅研究速递Abstract1003 video 2024ASCO年会中国医学论坛报学术联播 邀您一起快意前沿、...
At the 2024 ASCO, Henlius will release the extended follow-up results and patient-reported outcomes from the pivotal phase 3 clinical study (ASTRUM-005) of serplulimab for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) with Professor Ying Cheng from Jilin Cancer...
①Abstract 4003:EA2186 II 期随机对照试验是首个探索新诊断的转移性胰腺导管腺癌(mPDAC)老年患者最佳治疗策略的前瞻性研究[3]。 ②Abstract 4005:NRG Oncology/RTOG 0848 研究证实,术后辅助 5-FU/吉西他滨增敏化疗可改善壶腹周围癌...
Eric Small教授提到,今年ASCO年会是历届规模最大、参会人数最多的一届,来自全球的肿瘤领域研究进展齐放异彩,尤其是来自中国研究者的报告也在本次会议中占据重要地位——在今年ASCO全体大会系列专场Updates of the Abstract环节的6项重磅研究...
备受关注的ASCO Plenary Series: Rapid Abstract Updates(ASCO全体会议系列:摘要更新)将于6月1日12:30-13:30(芝加哥时间)在会议展馆的Arie Crown Theater举行,在该活动的6个摘要更新中,中国研究占据“半壁江山”: Updates on Abstract 434420: A Phase 1 Trial of Claudin 18.2-Specific Antibody-Drug Conjugate ...
其二是SKB264联合PD-L1单抗KL-A167一线治疗晚期非小细胞肺癌的临床二期OptiTROP-Lung01研究的最新数据（NCT05351788），将于Oral Abstract Session口头汇报，摘要号为8502。ADC+IO正在开启肿瘤免疫治疗新时代之际，科伦博泰也在积极布局。可见，成功牵手默沙东，并作为默沙东肿瘤管线未来的重要产品之一，SKB264正在国际舞台...
The abstract titledClinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate,will be presented as a poster on June 1, 2024. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The ...
Abstract Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the final results of the phase 3 ...
Key data from Merck’s pipeline to be presented at ASCO 2024: First presentation of three-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940) in combination with KEYTRUDA as adj...